



Marine-Derived Novel Drugs in the Treatment of Alzheimer's Disease

Guest Editor:

Dr. Zhipei Sang

School of Pharmaceutical
Sciences, Hainan University,
Haikou, China

Deadline for manuscript
submissions:

30 June 2026

Message from the Guest Editor

For this Special Issue, we aim to present the latest research and advancements in the identification of molecular targets for marine-derived compounds, offering insights into their potential applications in combating Alzheimer's disease (AD) and elucidating their mechanisms of action.

Alzheimer's disease is a progressive neurodegenerative disorder characterized by memory impairment and cognitive decline, for which there is currently a lack of effective treatments. The rich biodiversity of marine environments leads to a vast array of natural products with significant potential in drug discovery and development. Marine organisms have long been recognized as valuable sources of bioactive compounds with diverse chemical structures and pharmacological properties. We invite researchers from across different scientific disciplines to contribute their latest findings, reviews, and perspectives to this dynamic and interdisciplinary field. Through this Special Issue, we will strive to advance our understanding of the potential applications of marine natural products and their derivatives in the treatment of AD.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Bill J. Baker

Department of Chemistry,
University of South Florida, 4202
E. Fowler Ave., CHE 205, Tampa,
FL 33620-5250, USA

Message from the Editor-in-Chief

During the past few decades there has been an ever increasing number of novel compounds discovered in the marine environment. This is exemplified by the robust preclinical and clinical pipeline that currently exists for marine natural products. *Marine Drugs* is inviting contributions on new advances in marine biotechnology, pharmacology, chemical ecology, synthetic biology, and genomics approaches related to the discovery of therapeutically relevant marine natural products. Our goal is to share your contribution in a timely fashion and in a manner that will be valued by the scientific community.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [MEDLINE](#), [PMC](#), [Embase](#), [PubAg](#), [MarinLit](#), [AGRIS](#), and [other databases](#).

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmacology, Toxicology and Pharmaceutics (miscellaneous))

Contact Us

Marine Drugs Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/marinedrugs
marinedrugs@mdpi.com
[X@Marine_Drugs](#)